Exosome Applications

What are exosomes?

Exosomes are very small vesicles released outside cells to communicate with other cells. They may carry proteins, lipids and molecules containing genetic messages. Skin research explores how this communication might affect tissue repair and cellular responses.

They should not be regarded as an established standard treatment with fully predictable outcomes. Human studies are increasing, but products, routes and assessment methods differ considerably.

Exosomes are not stem cells

An exosome is not a cell: it cannot multiply or turn into another cell. Different cells, including stem cells, can release exosomes, but this does not mean that a resulting product contains living stem cells.

Products marketed as exosomes can differ considerably. Some contain purified extracellular vesicles, others cell-culture medium. Some combine vesicles with hyaluronic acid, amino acids, peptides, vitamins or other ingredients.

Different product groups

• Mesenchymal-cell-derived: cultures originating from tissues such as fat, bone marrow or umbilical cord may be used. Manufacturing conditions influence contents even with a similar source.
• Platelet-derived: products developed from platelet-released extracellular vesicles are not the same as PRP made from your own blood.
• Animal-derived: vesicles from bovine milk and particularly colostrum are being studied. Much of the skin-repair evidence is laboratory or animal research and cannot be equated directly with human-derived products or aesthetic injection outcomes.
• Plant-derived: these particles are more accurately described as exosome-like nanovesicles and should not be considered biologically identical to human or animal exosomes.
• Conditioned culture medium: this may contain vesicles alongside soluble proteins and other secreted products; it is not synonymous with isolated, purified exosomes.
• Combined formulations: added hyaluronic acid, amino acids, peptides, vitamins or antioxidants mean that the whole formula must be assessed rather than attributing every effect to exosomes.

What distinguishes products?

I assess the source alongside culture conditions, separation methods, particle count, purity and residual proteins. Sterility, storage and cold-chain handling also matter.

In combination formulas, the structure and quantity of hyaluronic acid, other ingredients and their compatibility for injection require assessment. It is not always possible to distinguish vesicle-related changes from carrier or added-ingredient effects.

I check traceability, analytical documentation, the whole formula's suitability for injection, the recommended route and storage conditions. If these are unclear, I do not consider the product suitable for intradermal injection.

How I apply them at my practice

I use direct injection of products whose suitability for injection has been verified, distributing small amounts into the selected areas and appropriate tissue plane.

This differs from applying a product on the skin after microneedling. An “exosome” label alone does not establish suitability for injection; the route must be checked for the specific product.

Which concerns may be considered?

Skin texture, dullness, fine lines, and the appearance of hydration and elasticity on the face and neck may be discussed. This does not replace filler for substantial volume loss, botulinum toxin for strong expression lines, or adequately address advanced laxity by itself.

Dryness and uneven texture can have different causes. I assess whether the method fits the intended change, rather than choosing it because it is popular.

When should the effect be assessed?

Early swelling or brightness can be a temporary injection effect. Published clinical studies commonly assess appearance at four to eight weeks, sometimes following participants to 12 weeks.

Direct injection has no established onset or duration that applies across all products. I assess the result after early swelling has settled, using consistent lighting and an appropriate review interval.

What I assess at the first consultation

• Skin needs: texture, sensitivity, dryness, active disease and expectations.
• Health: allergies, immune-related conditions, medicines and previous procedures.
• Product characteristics: source, composition, sterility, storage and verified suitability for direct injection.

Treatment and aftercare

After cleansing, fine needles deliver the preparation at planned sites. Small bumps, redness, tenderness, mild swelling or bruising may occur and often decrease over one to three days.

Initially avoid irritating skincare and intense heat, keep the area clean and follow individual advice. Increasing pain, warmth, marked redness or an unexpected reaction require contact with the practice.

Evidence and product safety

Early clinical findings are promising, but stronger human studies are needed for long-term safety, optimal dosing and standardised protocols. Injection data must be distinguished from topical or post-device data.

Source, purity, sterility, storage chain and intended route must be clear. Regulatory status varies between countries, so current product documentation is checked before treatment.

Frequently asked questions